SCHEMBL22720882

SCHEMBL22720882

Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CCN(C2CCN(C3CCN(C4CCNCC4)CC3)CC2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 17/20 0.75
LCK P06239 6/20 0.75
SRC P12931 5/20 0.75
TEK Q02763 2/20 0.75
KDR P35968 1/20 0.75
NUDT14 O95848 1/20 0.75
NUDT5 Q9UKK9 1/20 0.75
LYN P07948 2/20 0.74
EGFR P00533 4/20 0.66
ITK Q08881 3/20 0.59
ABL1 P00519 1/20 0.59
ERBB2 P04626 1/20 0.59
FYN P06241 1/20 0.59
YES1 P07947 1/20 0.59
HCK P08631 1/20 0.59
FGR P09769 1/20 0.59
FER P16591 1/20 0.59
CSK P41240 1/20 0.59
TEC P42680 1/20 0.59
BLK P51451 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6435508 1.00 BTK (0.75) BTKLCKSRCTEKKDR
SCHEMBL30144776 1.00 BTK (0.75) BTKLCKSRCTEKKDR
SCHEMBL22720857 1.00 BTK (0.75) BTKLCKSRCTEKKDR
SCHEMBL22737441 1.00 BTK (0.75) BTKLCKSRCTEKKDR
SCHEMBL22720837 0.96 BTK (0.71) BTKLCKSRCTEKKDR
SCHEMBL22720662 0.96 BTK (0.71) BTKLCKSRCTEKKDR
SCHEMBL22721073 0.96 BTK (0.71) BTKLCKSRCTEKKDR
SCHEMBL22720888 0.95 BTK (0.69) BTKLCKSRCTEKKDR
SCHEMBL24827991 0.95 BTK (0.72) BTKLCKSRCTEKKDR
SCHEMBL5801169 0.94 BTK (0.82) BTKLCKSRCTEKKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118027041-A BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof 西藏海思科制药有限公司 2024-05-14 CN disclosed
CN-113544130-B BTK inhibitor ring derivative and preparation method and pharmaceutical application thereof 西藏海思科制药有限公司 2024-01-09 CN disclosed
US-11542266-B1 Substituted piperidines as BTK inhibitors HAISCO PHARMACEUTICALS PTE. LTD. (SG) 2023-01-03 US disclosed
US-11542266-B1 Substituted piperidines as BTK inhibitors HAISCO PHARMACEUTICALS PTE. LTD. (SG) 2023-01-03 US disclosed
EP-3978496-A1 BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF Haisco Pharmaceuticals Pte. Ltd. (SG) 2022-04-06 EP disclosed
CN-113544130-A BTK inhibitor ring derivative, preparation method and pharmaceutical application thereof 四川海思科制药有限公司 2021-10-22 CN disclosed
WO-2020239103-A1 BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF 四川海思科制药有限公司 2020-12-03 WO disclosed
WO-2020239103-A1 BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF 四川海思科制药有限公司 2020-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11542266-B1 Substituted piperidines as BTK inhibitors BTK, BLK, SYK BTK 1/4885LCK 5/4885SRC 218/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.